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Ethical Evaluation of Pharmaceutical Marketing in Pakistan
M. Ahmad1, N. Akhtar1, M.H.A. Awan1, G. Murtaza2
Abstract: Our aim in this study is to give a broad overview of the main ethical and legal challenges of pharmaceutical market-
ing. The purpose of this study was also to investigate unethical pharmaceutical marketing, the effect on physicians of receiv-
ing gifts, the influences of perceptions regarding the importance of ethics and social responsibility on ethical intentions of 
marketing professionals. It also investigates the effect of unethical marketing on ultimate consumer (patient). Questionnaire 
based survey study was conducted from two main categories: (i) physicians/consultants and (ii) pharmaceutical companies. 
In Pakistan, there is no mechanism to monitor the drug promotional campaign by pharmaceutical industry despite the fact 
that there is enough evidence that irrational pharmacotherapy is increasingly encountered even in the developed countries 
due to unethical practices of pharmaceutical promotion. Medical practitioners and the pharmaceutical industry serve inter-
ests that sometimes overlap and sometimes conflict. There is strong evidence that associations between industry and physi-
cians influence the behaviour of the latter in relation to both clinical decision making and ethical promotion of drugs. The 
basic principles underlying the conduct of physicians with respect to pharmaceutical companies should be openness and 
transparency. 
Key words: pharmaceutical marketing, ethic in marketing, gifting to physician, physician-industry relationship, pharmaceu-
tical promotion and drug samples
Evaluación ética del mercado farmacéutico en Pakistán
Resumen: Nuestro objetivo es dar una amplia visión de los principales desafíos éticos y legales del mercado farmacéutico. El 
propósito de este estudio fue investigar faltas éticas en el mercado farmacéutico, el efecto de la recepción de regalos por parte 
de los medicos y la influencia de las percepciones respecto de la importancia de la ética y la responsabilidad social en las inten-
ciones éticas de los profesionales del mercado. También se investigó el efecto de las faltas éticas sobre el consumidor último (el 
paciente). Se realizó un estudio, mediante una encuesta cuestionario, con dos categorías principales: (i) médicos/consultores y 
(ii) empresas farmacéuticas. En Pakistán no existe un mecanismo para monitorear la campaña promocional de medicamentos 
realizada por la industria farmacéutica, a pesar de existir bastante evidencia de que ha aumentado la farmacoterapia irracional, 
incluso en países en desarrollo, debido a prácticas contrarias a la ética de la promoción farmacéutica. Los médicos practicantes 
y la industria farmacéutica sirven a intereses que algunas veces se superponen y otras entran en conflicto. Existe fuerte eviden-
cia de que las asociaciones entre la industria y los médicos influyen el comportamiento de los últimos, tanto en relación con la 
toma de decisiones clínicas como en la promoción contraria a la ética de medicamentos. La apertura y transparencia debieran 
ser los principios básicos que fundamenten la conducta de los médicos respecto de las empresas farmacéuticas. 
Palabras clave: mercado farmacéutico, ética de mercado, regalos a médicos, relación industria-médico, promoción farma-
céutica y muestras de medicamentos
Avaliação Ética do Mercado Farmacêutico no Paquistão
Resumo: Nosso objetivo é dar uma ampla visão dos principais desafios éticos e legais do mercado farmacêutico. O propósito 
deste estudo foi investigar faltas éticas no mercado farmacêutico, o efeito da recepção de brindes por parte dos médicos e 
a influência das percepções a respeito da importância da ética e da responsabilidade social nas intenções éticas dos profis-
sionais do mercado. Também se investigou o efeito das faltas éticas sobre o consumidor último (o paciente). Foi realizado 
um estudo, mediante um questionário, com duas categorias principais: (i) médicos/consultores e (ii) empresas farmacêuticas. 
No Paquistão não existe um mecanismo para monitorar a campanha promocional de medicamentos realizada pela indústria 
farmacêutica, apesar de existir bastante evidência de que tem aumentado a farmacoterapia irracional, inclusive em países 
em desenvolvimento, devido a práticas contrárias à ética da promoção farmacêutica. Os médicos praticantes e a indústria 
farmacêutica servem a interesses que algumas vezes se superpõem e em outras entram em conflito. Existe forte evidência de 
que as associações entre a indústria e os médicos influenciam o comportamento destes últimos, tanto em relação à tomada 
de decisões clínicas quanto na promoção contrária à ética dos medicamentos. A abertura e transparência deveriam ser os 
princípios básicos que fundamentam a conduta dos médicos a respeito das empresas farmacêuticas. 
Palavras-chave: mercado farmacêutico, ética de mercado, brindes a médicos, relação indústria-médico, promoção farmacêu-
tica e amostras de medicamentos
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Our aim in this study is to give a broad over-
view of the main ethical and legal challenges of 
pharmaceutical marketing. In many instances, 
these issues have not been resolved and the full 
debate remains to be done. Typically, there are no 
easy answers to the dilemmas raised, but aware-
ness of what the key issues are and sketching of 
directions will help healthcare professionals un-
derstand and participate in these developments. 
The main purpose of the present study is to in-
vestigate the influences of perceptions regarding 
the importance of ethics and social responsibility 
on ethical intentions of marketing professionals. 
This study also investigates the effects of unethical 
pharmaceutical marketing on health profession. 
 
Experimental
Market research is a process of gathering informa-
tion to help and make informed decisions about 
the marketing business. There are mainly two 
kinds of research methods: qualitative market re-
search and quantitative market research. Qualita-
tive research is a set of research techniques, used 
in marketing and the social sciences, in which 
data are obtained from a relatively small group 
of respondents and not analyzed with statistical 
techniques. This differentiates it from quantita-
tive research in which a large group of respon-
dents provides data that is statistically analyzed.
This study (2008/24-Pharm/IUB) was approved 
by the Board of Advance Study and Research, 
the Islamia University of Bahawalpur, Pakistan. 
Survey was conducted from two main categories: 
(i) physicians/consultants and (ii) pharmaceuti-
cal companies. Two questionnaires were designed 
for this purpose, one for physicians and other 
for pharmaceutical companies. Questionnaires 
for physicians contained 19 questions (table 1) 
and questionnaires for pharmaceutical compa-
nies contained 11 questions (table 2). Survey of 
physicians was conducted randomly throughout 
the country including four provinces as well as 
the northern areas of Pakistan. Survey of pharma-
ceutical companies was conducted randomly for 
national and multinational companies working in 
Pakistan.
Introduction
Marketing management is an art and science of 
choosing target markets and getting, keeping and 
growing customers through creating, delivering, 
and communicating superior customer value. 
Drug companies are moneymaking corporations 
just like any other; they exist to create a profit. 
The overarching aim of corporate drug promo-
tion, therefore, is to increase profits by raising 
consumer demand for pharmaceutical products. 
This market-driven approach fuels unethical 
drug promotion in several ways. The most com-
mon violations include: (i) promoting mislead-
ing or false claims about a drug, (ii) deliberately 
suppressing risks and side effects of a drug, (iii) 
providing financial incentives to physicians for 
prescribing drugs and (iv) using disease awareness 
campaigns for drug promotion rather than health 
promotion(1).
These methods can ultimately lead to irrational 
drug use by consumers, with potentially fatal 
health risks. Drug companies often say that they 
are providing a valuable information service and 
raising vital awareness about health matters. But 
the reality is that their unethical drug promotion 
methods can have serious implications for con-
sumer health and safety.
Because of the increasing attention to marketing 
ethics by the general public, marketing scholars 
have shown an intense interest in ethics as a re-
search area. It has been observed several theories 
in marketing ethics which developed over the last 
decade and these theories have led to numerous 
empirical studies of the ethical decision-making 
processes of marketing professionals(2). Some of 
these empirical studies focus on decision-making 
components of marketing ethics(3).
There is growing debate about the ethics of rela-
tionships between the pharmaceutical industry 
and the medical profession. Concerns include bias 
in research funded by the pharmaceutical industry 
and conflicts of interest with regard to prescribing 
by medical practitioners who accept industry gifts 
and hospitality. Benefits received from pharmaceu-
tical companies should leave physician’s and scien-
tist’s independence of judgment unimpaired(4).
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Data was collected from 400 physicians includ-
ing physicians as well as consultants. Out of 
these about half were consultants/specialists. One 
hundred pharmaceutical companies including 
national and multinational working in Pakistan 
were contacted for data collection. There was 
100% response rate from all respondents. The 
data was analyzed using Pearson Chi-Square test. 
The level of significance was set at 0.05.
 
Results
Physician response: The result shows that sam-
ple is a promotional tool which is used most 
frequently for pharmaceutical marketing. More 
than half (58%) physicians believe that pharma-
ceutical marketing is not satisfactory in Pakistan 
while 40% physicians are in favor the way by 
which pharmaceutical marketing is being done. 
The 100% of samples utilization by physicians is 
only 15% and only 50% of samples are utilized 
36% by physicians. More than 50% physicians 
admitted that self evaluation is the base for pre-
scription of medicine and literature survey is 2nd 
option for base for medicine prescription. The 
73% physicians believe that patient compliance 
is the key benefit for prescribing medicinal brand. 
Mostly 50% of physicians justified their-self for 
attending sale promotion officers. More than half 
(53%) physicians believe that ethical attitude is 
the factor which inspires them for SPO atten-
dance. Most (49%) of the SPO’s satisfy queries 
about new promotional drugs (figure 1).
Prescribing a newly launched drug cross match-
ing of literature is the base. More than half (53%) 
physician and consultants favor this factor for 
Physician’s name Specialist (Discipline) / General Physician
Age             years Hospital Sex Male    Female
1. What promotional tools pharmaceutical firms mostly use for pharmaceutical marketing? (Number with their preference)
Samples Giveaways Novelties Patient aids Medical exhibition
2. Are you satisfied with the way pharmaceutical marketing is being done? (Tick one)
Yes No
3. What percentage of the samples given by the marketing company is utilized by the ultimate customer (patients)? (Tick one)
A. 25% B. 50% C. 75% D. 100 %
4-What are the bases for prescribing the medicine? (Tick one)
Company image Percentage margin Personal relations
Self evaluation of medicinal brand Latest literature survey
5.  What is the key benefit for prescribing medicinal brand? (Tick one)
Financial benefit Personal relations Patient’s compliance Personal satisfactions
6. Do you justify yourself to attend Sale promotion officer (SPO)? (Tick one)
A. 25% B. 50% C. 75% D. 100 %
7. Select the option for Justification of question no. 6? (Tick one)
Financial benefit For knowledge Ethical attitude Insistence by SPO’ s
8.  What percentage of SPO does satisfy you queries about new promotional drug? (Tick one)
A. 25% B. 50% C. 75% D. 100% E. None
9. Before prescribing a newly launched drug, on what bases you justify yourself? (Tick one)
Cross matching the literature given by SPO’s 
with WHO standards
Literature provided by 
SPO’s
Company’s image Evaluation I Hit and 
Trial method
10. Which company’s Brand you prefer usually? (Please tick only one)
Homeopathic/Ayuervedic National Multinational Herbal
11. On which basis you prefer to prescribe above mention company’s brand? (Tick one)
Personal financial benefits Effectiveness of Brand Cost factor Company’s standards
12. Which way of marketing you appreciate by the company? (Tick one)
House hold goods gifting Company’s internal visits Recreational tours
Excessive free sampling None
13. Does frequent sampling helps you to determine quality of medicine for prescription? (Tick one)
Yes No
14. What kind of literature helps you to evaluate the drug? (Tick one)
Anatomical charts Pharmacological leaflets Photographic posters General information Others
I5. Do you think National or Multinational firms are spending more on their marketing and why?
National and Why Multinational and Why Both None No response
16. In your opinion among National and Multinational firms, which one are involved more in ethical marketing? (Tick one)
National Multinational Both None No response
17. Do you agree that pharmaceutical companies inspire you for unethical promotion of their products? (Tick one)
Yes No No response
I8. Who is the main culprit in promoting unethical marketing in your opinion? (Tick one)
A. Pharmaceutical companies B. Physicians C. SPO’s D. All E. No response
19. 1n your opinion how unethical marketing can be stopped?
Table 1. Questionnaire for Physicians/consultants
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Pharmaceutical company response: Sample is 
that promotional tool which is used most fre-
quently (84%) for pharmaceutical marketing. 
More than half (60%) pharmaceutical companies 
believe that pharmaceutical marketing is not sat-
isfactory in Pakistan. The 40% companies spend 
between 20-30% of their income on pharmaceu-
tical marketing (figure 4).
The 60% companies admit that trend of phar-
maceutical marketing in Pakistan is unethical. 
More than half (51%) pharmaceutical companies 
admit that they are responsible for trend of un-
ethical marketing in Pakistan. The 95% pharma-
ceutical companies believe that quality of drug is 
essential along with marketing. The 74% phar-
maceutical companies believe that bachelor of 
pharmacy is an ideal qualification for promotion 
of their products. The 85% pharmaceutical com-
panies claim that they organize ethical lectures 
among SPO’s to promote ethical pharmaceutical 
marketing. The 59% companies deny that incen-
tive/bonus schemes of pharmaceutical companies 
for SPO never inspire them toward unethical 
pharmaceutical marketing. Most (46%) orga-
prescribing a newly launched drug. The 73% 
physicians prefer multinational companies for 
their prescription. Most physicians (68%) prefer 
drugs on brand effectiveness bases. Excessive free 
sampling by companies to physicians is more ap-
preciated by physicians (59%). The 76% physi-
cians believe that frequent sampling help them in 
determining quality of drug for prescription. The 
75% prescribers (Physicians and Specialist) admit 
that pharmacological leaflets help them to evalu-
ate drug (figure 2).
Multinational pharmaceutical companies (36%) 
are spending more on marketing as compare to 
national pharmaceutical companies (22%). Mul-
tinational companies (74%) are more involved in 
ethical pharmaceutical practice. More than half 
(55%) physicians believe that pharmaceutical 
companies inspire them toward unethical drugs 
promotion. The 35% physicians believe that they 
are main culprit for unethical drug promotion but 
46 % physicians say that this unethical practice is 
due to pharmaceutical companies (figure 3). For 
all results, there was significant (p<0.05) difference 




1. What promotional tools pharmaceutical firms mostly use for pharmaceutical marketing? (Number with their preference)
Samples Giveaways Novelties
Patient aids Medical exhibitions
2. Are you satisfied with the way, pharmaceutical marketing is being done? (Tick one)
Yes No
3. How much %age of your income is spent on Pharmaceutical marketing? (Tick one)
A. 10 % B. 10-20 % C. 20-30 % D. More than 30%
4. Do- you think trend of pharmaceutical marketing in Pakistan is ethical or unethical? (Tick one)
Ethical Unethical Both
5. If trend is unethical, then in your opinion who is responsible for such behavior? (Tick one)
Pharmaceutical companies Physicians Sale promotion officers 
(SPOs)
Others
6. Do you think marketing is also essential along with quality of drugs? (Tick one)
Yes No No response
7. In your opinion which qualification of SPOs can be more effective for ethical pharmaceutical marketing? (Tick one)
A. Arts graduate B. Science graduate C. Pharmacy graduate D. MBBS
8. Do your organization organize any ethical lectures among the SPO’s to promote ethical pharmaceutical marketing? (Tick 
one)
Yes No No response
9. Do you think Incentive/Bonus schemes of pharmaceutical companies for SPOs inspire them toward unethical pharmaceutical 
marketing? (Tick one)
Yes No No response
10. Do your organization participate in medical/pharmaceutical ‘conferences and seminars by providing followings? 
(Tick one)
Sponsoring overhead Expenses Distributing gifts Foods Hosting meal
11. In your opinion how unethical marketing can be stopped?
Table 2. Questionnaire for pharmaceutical industries
 219
Acta Bioethica  2011; 17 (2): 215-224
achievement of sales targets, which might tilt the 
balance in favor of aggressive drug promotion(7). 
More than 95% pharmaceutical companies say 
that quality of drug is essential along market-
ing. For better promotion of their drugs most 
pharmaceutical companies claim that pharmacist 
is better choice for them. The industry spends 
about $12 billions a year on gifts and payments to 
physicians, funds more than 70% of clinical trials, 
and shoulders more than half the costs of formal 
continuing education programmes in medicine. 
Financial entanglement has bred close ties be-
tween the industry and physicians. Contacts with 
trainees come early and continue as they move 
into practice(8). Majority of the companies are 
spending about 20-30 % on marketing. Most 
companies (46 %) claim that they distribute gifts 
in medical conferences organize by them.
Though simple gifts may not directly influence 
prescription practices, they would not be distrib-
uted unless they had some related impact. It has 
been pointed out that a policy of limiting gift size 
is unlikely to eliminate bias, because ‘even small 
gifts can subtly bias how arguments are evaluated, 
they can be surprisingly influential(9). Physicians 
say that both national and multinational com-
panies are spending much on their marketing 
promotion activities. Drug spending increased by 
17% to $154.5 billion in 2001, with an estimated 
one quarter of this increase resulting from a shift 
to the prescribing of more expensive drugs. Phar-
maceutical companies employ representatives 
who meet with physicians with apparent suc-
cess to aggressively promote newer and typically 
more expensive drugs. A positive correlation has 
been found between the cost of physicians’ treat-
ment choices and their amount of contact with 
pharmaceutical company representatives(10,11). 
Wazana concluded on the basis of a review of 29 
empirical articles that physician interactions with 
pharmaceutical companies led to increased pre-
scription costs and non-rational prescribing. This 
increase is problematic, given the prevalence of 
new, expensive drugs of questionable incremental 
value(12).
Another important issue which came in front dur-
ing such discussion was that what we say ethical 
and what is unethical, as different physician have 
their own point of view about this issue. Most 
nizations participate in medical/pharmaceutical 
conferences and seminars by providing gifts and 
funds (figure 5). For all results, there was signifi-




Drug promotion can take on many forms. Overt 
promotion, such as magazine advertisements, free 
product samples and visits to physicians by medi-
cal sales representatives are tried tested methods 
of pushing new product lines(5).
In Pakistan, there is no mechanism to monitor 
the drug promotional campaign by pharmaceuti-
cal industry despite the fact that there is enough 
evidence that irrational pharmacotherapy is in-
creasingly encountered even in the developed 
countries due to unethical practices of pharma-
ceutical promotion(6). Conflicts of interest can 
arise from other financial ties between physicians 
and industry, whether to outside companies or 
self-owned businesses. Such ties include honorari-
ums for speaking or writing about a company’s 
product, payment for participating in clinic-
based research, and referrals to medical resources. 
All of these relationships have the potential to in-
fluence a physician’s attitudes and practices. This 
paper explores the ethical quandaries involved 
and offers guidelines. About 60% pharmaceuti-
cal companies and 40% physicians are not satis-
fied with trend of pharmaceutical marketing in 
Pakistan. Both have different opinions about this 
unethical trend. Physicians blame pharmaceuti-
cal companies due to their unethical promotional 
tools while companies think they can do nothing 
without will of physicians. More than half phar-
maceutical companies believe that there is unethi-
cal pharmaceutical marketing in Pakistan, while 
physicians believe that bonus schemes of pharma-
ceutical companies inspire them toward unethical 
attitude.
Every pharmaceutical company employs and 
trains medical representatives to promote and 
sell drugs, using printed product literatures, drug 
samples and gifts. In India, an estimated 40,000 
representatives are employed by the industry. Be-
sides the salaries, they also receive incentives for 
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of non-compliance or malpractices, effective sanc-
tions and mechanisms to correct misinformation 
should be well-defined.
Secondly, we need to teach our physicians the art 
of critical appraisal of medicinal drug promotion 
possibly during their undergraduate training so 
that they would be able to write rational prescrip-
tions. Another step towards improvement could be 
reassessing the knowledge of all practicing physi-
cians regarding drugs available in the market. This 
assessment should be according to the interna-
tional standards and should be compulsory for the 
physician to have an attempt after a specified time. 
This would compel the physicians to look up to 
the authentic medical literature for reference in-
stead of relying solely on the promotional materi-
al(6). For ethical marketing promotion about 85% 
companies claim that they organize ethical lectures 
among their sales promotion officers.
During survey a comprehensive discussion was 
done with Physicians and Marketing managers 
of pharmaceutical companies. There was a vast 
difference among national and multi-national 
companied about their marketing strategies. Na-
tional companies blame that multi-national firms 
inspire them toward unethical marketing while 
multi-national companies have their own point 
of view that they never compromise on quality 
of drugs.
A conflict of interest exists when a primary ethical 
or professional interest clashes with financial self-
interest, a situation that arises commonly in medi-
cal practice. When physicians are remunerated for 
performing specific tests and procedures, they face 
a conflict of interest when they also recommend 
those same tests and procedures. When they are 
paid for referrals to clinical trials, physicians are in 
the conflicted position of deciding whether their 
patients are appropriate for the studies. Perform-
ing industry-supported research, physicians face 
an implicit demand for a positive finding to ob-
tain further financial support. And, when pharma-
ceutical companies court high-volume prescribers, 
writing prescriptions becomes an act not only with 
financial and health consequences for patients, but 
also with financial consequences for the physician. 
This last source of conflict of interest is the central 
focus of this commentary(13).
physicians claim that gifting, giveaways and nov-
elties are not unethical and pharmaceutical com-
panies are responsible for such type of unethical 
marketing. But they were answerless when asked 
that whether such promotional tools have no ef-
fect on their prescription habits? Some physician 
while most consultants believe that pharmaceu-
tical companies can never compel them toward 
unethical attitude if they are not looking forward 
for their own interests. During survey most phy-
sicians (over 35%) took responsibility of such 
unethical behavior while 46% pharmaceutical 
companies took responsibility of such unethical 
practice.
Sampling is the most frequently used promotion-
al tool (84%) and most pharmaceutical compa-
nies are using this promotional tool for promo-
tion of their drugs. About utilization of samples 
50% physicians claim that 50% samples provided 
by companies are given to patients and physi-
cians (60%) also appreciate free excessive sam-
pling.  About 76% physicians say that frequent 
sampling help them for proper evaluation of drug 
quality. Gifts from the pharmaceutical industry 
contribute to the rapidly increasing cost of medi-
cal care, and more specifically, to the increase in 
expenditures on prescription drugs. Retail spend-
ing on prescriptions has increased rapidly, more 
than doubling from $64.7 billion to $132 billion 
in the years 1995-2000. Gifting is done both by 
multinational and national pharmaceutical com-
panies.
About 73% physicians prefer multinational com-
panies brands and they claim that their preference 
is due to brand effectiveness. About 56% physi-
cians prescribe medicines on self evaluation base 
and second option is literature survey, while 76% 
physicians believe that pharmacological leaflets 
help them for drug evaluation. 
Along all other requirements we also need to have 
well-defined and updated ethical criteria for the 
marketing of medicinal drugs by the pharmaceuti-
cal companies. These criteria need to be enforced 
by a public institution, preferably the Ministry of 
Health. In order to ensure that the ethical criteria 
are being implemented, there is a need for screen-
ing of printed promotional material and active 
monitoring of other forms of promotion. In cases 
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Strengths of study 
Strengths of our study include collection of data 
from physician and pharmaceutical companies. 
Both questionnaires from physician and phar-
maceutical companies contain stamp and sign of 
physician and marketing managers, respectively. 
Data was collected from general physicians and 
consultants for proper evaluation. Similarly, both 
national and multi-national pharmaceutical com-
panies were included in survey. Sample size was 
also large and whole Pakistan including all four 




There was no variety in designing of different 
questions. Number of questions was also less. De-
spite it, our study strongly suggests that in Paki-
stan there is a need of proper rules and regulation 
about ethical pharmaceutical marketing.
Conclusion
Physicians appeared to believe that most of these 
promotional activities do not pose major ethical 
problems. It is concluded that many physicians 
made distinctions about ethical appropriateness 
that reflected the value of a gift, the type of gift, 
and the extent to which an activity conveys po-
tentially biased information. The pharmaceutical 
companies should provide them the latest medi-
cal research literature by post. Pharmaceutical 
companies focus on this issue that there should 
be some proper rules and regulations about pre-
scription of drugs. Physicians were more con-
scious and feel fear while admitting their fault 
but consultants were bold to answer that they are 
the main culprit for such unethical pharmaceu-
tical marketing. No doubt they blame to phar-
maceutical firm as well but they admit that if 
our community took step then all will be right. 
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Figure 1. Response from physicians (question 1-8)
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Figure 2. Response from physicians (question 9-14)
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Figure 3. Response from physicians (question 15-18)
	  
Figure 4. Response from pharmaceutical companies (question 1-3)
